Information on MMS available - no active implementation
Research study on the impact of lipid-based nutrient supplement on pregnant women published and cost-benefit analysis for MMS available.
Significant progress has been made, including the establishment of an MMS Taskforce, revision of antenatal care guidelines to include MMS, and advanced steps toward MMS inclusion in the Essential Medicines List (EML). MMS-specific social behavior change materials have been developed and pre-tested. The inclusion of MMS in the EML will support engagements within the government on co-financing, including funding for delivery system strengthening. Capacity building for healthcare providers and formative research are planned. Challenges include varying stakeholder interpretations of WHO recommendations, delays in offshore MMS supply procurement, and some confusion between MMS for pregnant women and IFA for adolescent girls. Lessons learned include that MMS rollout strengthens maternal nutrition interventions, research evidence and MMS inclusion in WHO’s EML are crucial, and sustaining MMS beyond research requires ongoing advocacy.
Last updated: January 2025